Propionibacterium (Cutibacterium) acnes Bacteriophage Therapy in Acne: Current Evidence and Future Perspectives

David E. Castillo, Sonali Nanda, Jonette Keri

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Acne vulgaris is the most common dermatological disorder worldwide. It is a multifactorial disease that involves increased sebum production, hyperkeratinization of the pilosebaceous unit, Propionibacterium acnes (Cutibacterium acnes) colonization, and inflammation. The human skin microbiome hosts a wide variety of microorganisms, including bacteria, viruses, and fungi. A delicate balance of these microorganisms is essential for the barrier function of the skin. Propionibacterium acnes represents nearly 90% of the human skin microbiome of healthy adults. Acne is a chronic recurrent disease that requires long-lasting treatment, which has led to the emergence of antibiotic resistance. New alternatives to traditional therapy are emerging, including antimicrobial peptides, natural engineered antibodies, and bacteriophages. Bacteriophages have been shown to play a role in human skin health and disease. There is evidence supporting phage therapy in many types of skin infections. P. acnes bacteriophages have been isolated and characterized. However, only a few in vitro studies have tested the ability of bacteriophages to kill P. acnes. Furthermore, there is no evidence on bacteriophage therapy in the treatment of acne in humans. In this review, we summarize the most recent evidence regarding P. acnes bacteriophages and the potential role of these bacteriophages in the treatment of acne. Further research on this field will provide the evidence to use phage therapy to decrease rates of antibiotic resistance and restore antibiotic susceptibility of P. acnes.

Original languageEnglish (US)
Pages (from-to)19-31
Number of pages13
JournalDermatology and Therapy
Volume9
Issue number1
DOIs
StatePublished - Mar 1 2019

Fingerprint

Propionibacterium acnes
Acne Vulgaris
Bacteriophages
Skin
Microbiota
Microbial Drug Resistance
Sebum
Therapeutics
Skin Diseases
Phage Therapy
Chronic Disease
Fungi
Anti-Bacterial Agents
Viruses
Inflammation
Bacteria
Peptides
Antibodies
Health
Infection

Keywords

  • Acne
  • Antibiotic resistance
  • Bacteriophages
  • Microbiome
  • Phage therapy
  • Phages
  • Propionibacterium acnes

ASJC Scopus subject areas

  • Dermatology

Cite this

Propionibacterium (Cutibacterium) acnes Bacteriophage Therapy in Acne : Current Evidence and Future Perspectives. / Castillo, David E.; Nanda, Sonali; Keri, Jonette.

In: Dermatology and Therapy, Vol. 9, No. 1, 01.03.2019, p. 19-31.

Research output: Contribution to journalReview article

@article{1acb711f254d4cabb9b47cec56201016,
title = "Propionibacterium (Cutibacterium) acnes Bacteriophage Therapy in Acne: Current Evidence and Future Perspectives",
abstract = "Acne vulgaris is the most common dermatological disorder worldwide. It is a multifactorial disease that involves increased sebum production, hyperkeratinization of the pilosebaceous unit, Propionibacterium acnes (Cutibacterium acnes) colonization, and inflammation. The human skin microbiome hosts a wide variety of microorganisms, including bacteria, viruses, and fungi. A delicate balance of these microorganisms is essential for the barrier function of the skin. Propionibacterium acnes represents nearly 90{\%} of the human skin microbiome of healthy adults. Acne is a chronic recurrent disease that requires long-lasting treatment, which has led to the emergence of antibiotic resistance. New alternatives to traditional therapy are emerging, including antimicrobial peptides, natural engineered antibodies, and bacteriophages. Bacteriophages have been shown to play a role in human skin health and disease. There is evidence supporting phage therapy in many types of skin infections. P. acnes bacteriophages have been isolated and characterized. However, only a few in vitro studies have tested the ability of bacteriophages to kill P. acnes. Furthermore, there is no evidence on bacteriophage therapy in the treatment of acne in humans. In this review, we summarize the most recent evidence regarding P. acnes bacteriophages and the potential role of these bacteriophages in the treatment of acne. Further research on this field will provide the evidence to use phage therapy to decrease rates of antibiotic resistance and restore antibiotic susceptibility of P. acnes.",
keywords = "Acne, Antibiotic resistance, Bacteriophages, Microbiome, Phage therapy, Phages, Propionibacterium acnes",
author = "Castillo, {David E.} and Sonali Nanda and Jonette Keri",
year = "2019",
month = "3",
day = "1",
doi = "10.1007/s13555-018-0275-9",
language = "English (US)",
volume = "9",
pages = "19--31",
journal = "Dermatology and Therapy",
issn = "2190-9172",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Propionibacterium (Cutibacterium) acnes Bacteriophage Therapy in Acne

T2 - Current Evidence and Future Perspectives

AU - Castillo, David E.

AU - Nanda, Sonali

AU - Keri, Jonette

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Acne vulgaris is the most common dermatological disorder worldwide. It is a multifactorial disease that involves increased sebum production, hyperkeratinization of the pilosebaceous unit, Propionibacterium acnes (Cutibacterium acnes) colonization, and inflammation. The human skin microbiome hosts a wide variety of microorganisms, including bacteria, viruses, and fungi. A delicate balance of these microorganisms is essential for the barrier function of the skin. Propionibacterium acnes represents nearly 90% of the human skin microbiome of healthy adults. Acne is a chronic recurrent disease that requires long-lasting treatment, which has led to the emergence of antibiotic resistance. New alternatives to traditional therapy are emerging, including antimicrobial peptides, natural engineered antibodies, and bacteriophages. Bacteriophages have been shown to play a role in human skin health and disease. There is evidence supporting phage therapy in many types of skin infections. P. acnes bacteriophages have been isolated and characterized. However, only a few in vitro studies have tested the ability of bacteriophages to kill P. acnes. Furthermore, there is no evidence on bacteriophage therapy in the treatment of acne in humans. In this review, we summarize the most recent evidence regarding P. acnes bacteriophages and the potential role of these bacteriophages in the treatment of acne. Further research on this field will provide the evidence to use phage therapy to decrease rates of antibiotic resistance and restore antibiotic susceptibility of P. acnes.

AB - Acne vulgaris is the most common dermatological disorder worldwide. It is a multifactorial disease that involves increased sebum production, hyperkeratinization of the pilosebaceous unit, Propionibacterium acnes (Cutibacterium acnes) colonization, and inflammation. The human skin microbiome hosts a wide variety of microorganisms, including bacteria, viruses, and fungi. A delicate balance of these microorganisms is essential for the barrier function of the skin. Propionibacterium acnes represents nearly 90% of the human skin microbiome of healthy adults. Acne is a chronic recurrent disease that requires long-lasting treatment, which has led to the emergence of antibiotic resistance. New alternatives to traditional therapy are emerging, including antimicrobial peptides, natural engineered antibodies, and bacteriophages. Bacteriophages have been shown to play a role in human skin health and disease. There is evidence supporting phage therapy in many types of skin infections. P. acnes bacteriophages have been isolated and characterized. However, only a few in vitro studies have tested the ability of bacteriophages to kill P. acnes. Furthermore, there is no evidence on bacteriophage therapy in the treatment of acne in humans. In this review, we summarize the most recent evidence regarding P. acnes bacteriophages and the potential role of these bacteriophages in the treatment of acne. Further research on this field will provide the evidence to use phage therapy to decrease rates of antibiotic resistance and restore antibiotic susceptibility of P. acnes.

KW - Acne

KW - Antibiotic resistance

KW - Bacteriophages

KW - Microbiome

KW - Phage therapy

KW - Phages

KW - Propionibacterium acnes

UR - http://www.scopus.com/inward/record.url?scp=85061809102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061809102&partnerID=8YFLogxK

U2 - 10.1007/s13555-018-0275-9

DO - 10.1007/s13555-018-0275-9

M3 - Review article

AN - SCOPUS:85061809102

VL - 9

SP - 19

EP - 31

JO - Dermatology and Therapy

JF - Dermatology and Therapy

SN - 2190-9172

IS - 1

ER -